A phase 2 study of SBP-9330 for nicotine cessation
Latest Information Update: 09 Feb 2024
At a glance
- Drugs SBP-9330 (Primary)
- Indications Smoking withdrawal
- Focus Therapeutic Use
Most Recent Events
- 09 Feb 2024 New trial record
- 06 Feb 2024 According to a Camino Pharma media release, $9-million grant (U01DA057847) from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) will fund toxicology studies and drug manufacturing of SBP-9330 to support planned Phase 2 studies for nicotine cessation.